- Home
- TTNP vs JAGX Comparison
TTNP vs JAGX Comparison
Compare TTNP & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- JAGX
- Stock Information
- Founded
- TTNP 1991
- JAGX 2013
- Country
- TTNP United States
- JAGX United States
- Employees
- TTNP N/A
- JAGX N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- JAGX Health Care
- Exchange
- TTNP Nasdaq
- JAGX Nasdaq
- Market Cap
- TTNP 3.4M
- JAGX 3.8M
- IPO Year
- TTNP 1996
- JAGX N/A
- Fundamental
- Price
- TTNP $3.70
- JAGX $10.91
- Analyst Decision
- TTNP
- JAGX
- Analyst Count
- TTNP 0
- JAGX 0
- Target Price
- TTNP N/A
- JAGX N/A
- AVG Volume (30 Days)
- TTNP 9.7K
- JAGX 211.5K
- Earning Date
- TTNP 05-14-2025
- JAGX 05-13-2025
- Dividend Yield
- TTNP N/A
- JAGX N/A
- EPS Growth
- TTNP N/A
- JAGX N/A
- EPS
- TTNP N/A
- JAGX N/A
- Revenue
- TTNP N/A
- JAGX $11,689,000.00
- Revenue This Year
- TTNP N/A
- JAGX $38.22
- Revenue Next Year
- TTNP N/A
- JAGX $39.96
- P/E Ratio
- TTNP N/A
- JAGX N/A
- Revenue Growth
- TTNP N/A
- JAGX 19.75
- 52 Week Low
- TTNP $3.03
- JAGX $4.02
- 52 Week High
- TTNP $14.80
- JAGX $540.00
- Technical
- Relative Strength Index (RSI)
- TTNP 49.54
- JAGX 70.55
- Support Level
- TTNP $3.53
- JAGX $5.00
- Resistance Level
- TTNP $3.76
- JAGX $6.13
- Average True Range (ATR)
- TTNP 0.20
- JAGX 1.37
- MACD
- TTNP -0.00
- JAGX 0.94
- Stochastic Oscillator
- TTNP 32.79
- JAGX 60.12
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.